India Proposes Classifying Manipulated Cells And Tissue Products As Drugs
The Indian government is proposing to change the definition of a new drug to include substantially manipulated stem cell and tissue-based therapies.
You may also be interested in...
Draft update to national guidelines factors in additional safeguards and makes it mandatory to establish institutional panels to review stem cell research. Gene editing would be an area of "restrictive" research.
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.